Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., . . . Mutis, T. (2015). Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica.

Nijhof, Inger S., Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J van de Donk, Paul W.H.I Parren, and Tuna Mutis. "Daratumumab-mediated Lysis of Primary Multiple Myeloma Cells Is Enhanced in Combination With the Human Anti-KIR Antibody IPH2102 and Lenalidomide." Haematologica 2015.

Nijhof, Inger S., et al. "Daratumumab-mediated Lysis of Primary Multiple Myeloma Cells Is Enhanced in Combination With the Human Anti-KIR Antibody IPH2102 and Lenalidomide." Haematologica 2015.